FAT jabs can treat a liver disease affecting one in five people, a trial found.
Semaglutide cut inflammation in two thirds of patients with .
The is used in injection and treatment .
is triggered by excess flab which causes unhealthy fat cells to build up.
It has no specific cure and may cause in later life.
In the study, King’s College looked at the jabs’ impact on 800 patients with the disease.
After 18 months, 63 per cent showed a reduction in swelling and fatty build-up in their liver.
They also had blood test results and lost nearly 11 per cent of their weight.
Study author Professor Philip Newsome said: “This trial will provide real hope for patients.”;
